

Livdelzi[®] (seladelpar)

Use in Patients With Primary Sclerosing Cholangitis

This document is in response to your request for information regarding the use of Livdelzi[®] (seladelpar [SEL]) in patients with primary sclerosing cholangitis (PSC).

Some data may be outside of the US FDA-approved prescribing information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA-approved prescribing information.

The full indication, important safety information, and boxed warnings are available at: www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.

Product Labeling¹

Indications and Usage

SEL is indicated for the treatment of PBC in combination with UDCA in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.

This indication is approved under accelerated approval based on a reduction of alkaline phosphatase. Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Limitations of Use: Use of SEL is not recommended in patients who have or develop decompensated cirrhosis (eg, ascites, variceal bleeding, hepatic encephalopathy).

Clinical Data on SEL Use in Patients With PSC

Currently, there are no clinical data or guidance on the use of SEL in patients with PSC.

In the completed and ongoing SEL phase 3 trials (ie, RESPONSE, ENHANCE, and ASSURE), PSC determined by the presence of diagnostic cholangiographic findings was an exclusion criterion. A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, and efficacy of SEL administered for 24 weeks in adult patients with PSC was terminated early as a precautionary measure due to unexpected histological findings that were later determined to be preexisting in the nonalcoholic steatohepatitis SEL program.²⁻⁴

Additionally, a literature search was conducted in Ovid MEDLINE and Embase databases for studies published up to January 15, 2026, using search terms that included Livdelzi, seladelpar, primary sclerosing cholangitis, and related search terms. No relevant citations were found.

References

1. Livdelzi Gilead Sciences Inc. LIVDELZI® (seladelpar) capsules, for oral use. US Prescribing Information. Foster City, CA.
 2. Hirschfield GM, Shiffman ML, Gulamhusein A, et al. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study [Supplement]. Hepatology. 2023;1-37.
 3. Hirschfield GM, Bowlus CL, Mayo MJ, et al. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.[Supplementary Appendix]. N Engl J Med. 2024;390(9):783-794.
 4. ClinicalTrials.gov. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC). Available at: <https://clinicaltrials.gov/study/NCT03301506?term=NCT03301506&rank=1>.
-

Abbreviations

PBC=primary biliary
cholangitis

PSC=primary sclerosing
cholangitis
SEL=seladelpar

UDCA=ursodeoxycholic
acid

Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Livdelzi US Prescribing Information available at:

www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.

Follow Up

For any additional questions, please contact Gilead Medical Information at:

☎ 1-866-MEDI-GSI (1-866-633-4474) or 🌐 www.askgileadmedical.com

Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or

🌐 www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉ MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🌐 www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers, and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact gilead.privacy@gilead.com.

LIVDELZI, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

© 2026 Gilead Sciences, Inc.